Karyopharm Therapeutics | KPTI - Sales Revenues


Karyopharm Therapeutics reported $34.08M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Abbott USD 11.16B 300M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Incyte USD 1.27B 240M Mar/2026
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Takeda JPY 1.09T 100B Mar/2026
Tectonic Therapeutic USD 0 0 Dec/2024
TG Therapeutics USD 194.8M 2.23M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026